chufangao/CTO huggingface dataset:
Clinical trial NCT02901483: A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Official title: A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Sponsor: PharmaEngine (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: bussiness reason
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-11
Primary completion date: 2020-08-17
Completion date: 2020-08-17
Clinical trial NCT05950776: COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults
Official title: A Multi-center, Randomized Placebo-controlled Phase II Trial to Assess the Safety, Tolerability and Immunogenicity of Two Doses of the Candidate Vaccine MVA-SARS-2-S in Adults Aged 18 to 64 and 65 and Older
Sponsor: Universitätsklinikum Hamburg-Eppendorf (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Results from Phase 1 lead to the decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-01-15
Primary completion date: 2022-11-02
Completion date: 2022-11-02
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02397356: Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia
Official title: Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia
Sponsor: Tampere University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of study personnel
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT03998709: Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion
Official title: Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: results from other study suggest no good reason to proceed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-01
Primary completion date: 2021-12-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT02552225: Treatment of Chronic Laryngitis With Amitriptyline
Official title: Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline
Sponsor: Boston Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Funding was not obtained so the study could not be continued after the Covid pause.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2021-01-15
Completion date: 2021-01-15
Limitations and caveats: Funding was not obtained so the study could not be continued after the Covid pause.
Plan to share individual participant data: NO
Clinical trial NCT03612739: EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
Official title: An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administered Concurrently With 5-azacytidine in Treatment-naïve Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients Not Candidates for Intensive Therapy
Acronym: EPITHINK
Sponsor: Celyad Oncology SA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-12-31
Primary completion date: 2019-05-31
Completion date: 2021-08-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03260972: Intraabdominal Chloroprocaine During Cesarean Delivery for Pain Control
Official title: An Evaluation of Intraabdominal Chloroprocaine During Cesarean Delivery and Its Effect on Postoperative Pain and Nausea; a Randomized Controlled Trial & Pharmacokinetic-pharmacodynamics (PKPD) Analysis.
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Withdrawn by IRB
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-30
Primary completion date: 2023-04-30
Completion date: 2023-06-30
Plan to share individual participant data: NO
IPD sharing description: No personal patient data will be shared with other researchers. The final de-identified manuscript will be published.
Clinical trial NCT04000555: Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
Official title: A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
Sponsor: University of South Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: The study was terminated early due to low enrollment, this was partially related to our ability to recruit during the COVID-19 pandemic.
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-01
Primary completion date: 2022-06-11
Completion date: 2022-06-11
Clinical trial NCT02265406: PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone
Official title: PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone
Acronym: PROPHY-VAP
Sponsor: Poitiers University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 354.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-10-31
Primary completion date: 2020-07-25
Completion date: 2020-07-25
Clinical trial NCT03371251: Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
Official title: A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
Sponsor: Boston Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 143.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-01-10
Primary completion date: 2020-11-26
Completion date: 2020-11-26
Clinical trial NCT02788292: Effect of N-Acetylcysteine on Autologous Fat Graft Survival
Official title: Effect of N-Acetylcysteine on Autologous Fat Graft Survival
Sponsor: Nova Scotia Health Authority (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: unable to hire research staff
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-15
Primary completion date: 2020-11-16
Completion date: 2020-11-16
Plan to share individual participant data: NO
IPD sharing description: IPD will not be available, but will be published as an average of outcomes.
Clinical trial NCT02683018: Investigation of Cannabis for Chronic Pain and Palliative Care
Official title: Investigation of Cannabis for Chronic Pain and Palliative Care
Sponsor: New York State Psychiatric Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Primary completion date: 2021-10-28
Completion date: 2021-10-28
Plan to share individual participant data: NO
Clinical trial NCT03393481: Prevention of Thromboembolic Events in Total Knee Replacement Patients
Official title: A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Active-controlled Phase 2 Study to Compare the Efficacy and Safety of s.c. MAA868 Versus s.c. Enoxaparin in Adult Patients Undergoing Unilateral Total Knee Arthroplasty
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Trial cancelled before First Patient First Visit (no patient enrolled)
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-03
Primary completion date: 2020-01-08
Completion date: 2020-04-17
Plan to share individual participant data: UNDECIDED
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT00942331: Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Official title: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 506.0 (ACTUAL)
Number of arms: 2.0
Start date: 2009-07-15
Primary completion date: 2018-11-02
Completion date: 2021-06-15
Clinical trial NCT02296112: Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations
Official title: A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations
Sponsor: Vanderbilt-Ingram Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-01-31
Primary completion date: 2018-08-31
Completion date: 2021-04-16
Clinical trial NCT03450707: Thiamine as a Metabolic Resuscitator After Cardiac Arrest
Official title: Thiamine as a Metabolic Resuscitator After Cardiac Arrest
Acronym: THACA
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: DSMB recommendation based on differing mortality in a subgroup analysis
Enrollment: 93.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-06
Primary completion date: 2022-02-19
Completion date: 2022-02-19
Limitations and caveats: The study was stopped early by the Data Safety and Monitoring Board (DSMB) due to a signal of increased mortality in the thiamine group with a lactate \> 5
Plan to share individual participant data: NO
Clinical trial NCT03726333: Hepatic Impairment Study for Lorlatinib in Cancer Patients
Official title: A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study stopped due to lack of enrollment
Enrollment: 1.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-01-14
Primary completion date: 2021-07-08
Completion date: 2021-07-08
Limitations and caveats: The study was terminated due to difficulties with enrolling eligible patients. Only 1 participant was enrolled in this study. Outcome measures and AE data were not reported as planned in the protocol because doing so would risk re-dentification of the individual participant.
Plan to share individual participant data: NO
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT01283997: Prevention of Treatment Induced Neuropathy in Multiple Myeloma
Official title: A Phase II Study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 79.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-01-25
Primary completion date: 2022-08-22
Completion date: 2022-08-22
Clinical trial NCT02974725: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Official title: A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 241.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-02-24
Primary completion date: 2024-04-24
Completion date: 2024-04-24
Plan to share individual participant data: NO
Clinical trial NCT04291508: Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Official title: Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Acronym: ASTER
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 488.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-10-13
Primary completion date: 2023-04-27
Completion date: 2023-07-27
Baseline population: There were 487 participants randomized. For baseline variables that were missing, the measure analysis population differs from the baseline analysis population. For these variables, a footnote identifies the reason for the discrepancy.
Clinical trial NCT00745134: Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer
Official title: A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The trial was stopped early because there was only one patient with pCR among the first 15 patients randomized to the curcumin arm.
Enrollment: 22.0 (ACTUAL)
Number of arms: 2.0
Start date: 2008-08-11
Primary completion date: 2022-11-11
Completion date: 2022-11-11
Clinical trial NCT05414006: Effect of S-ketamine in Cesarean Section Combined Anesthesia
Official title: Effect of S-ketamine in Cesarean Section Combined Anesthesia
Sponsor: The Second Affiliated Hospital of Chongqing Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-06-14
Primary completion date: 2022-08-31
Completion date: 2022-09-05
Plan to share individual participant data: YES
IPD sharing description: The individual participant data for this study is available from the sponsor on reasonable request through email
IPD time frame: Within five years
Clinical trial NCT05227131: Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
Official title: A Phase II Trial of Margetuximab in Combination With Tucatinib and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer
Acronym: MARGARET
Sponsor: MedSIR (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Funder decided to not continue the study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-15
Primary completion date: 2024-10-31
Completion date: 2024-10-31
Clinical trial NCT04776746: Open-Label Extension Study of Trofinetide for Rett Syndrome
Official title: An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.
Enrollment: 77.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-08
Primary completion date: 2023-06-30
Completion date: 2023-06-30
Baseline population: All patients enrolled and treated with trofinetide
Limitations and caveats: As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product. Date of study termination was 30 June 2023.
Plan to share individual participant data: NO
Clinical trial NCT04044209: A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Official title: A Phase II of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No patients were able to be screened nor enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-12
Primary completion date: 2021-09-30
Completion date: 2023-09-30
Clinical trial NCT04921358: Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Official title: SAFFRON-301: A Randomized Phase 3 Study of Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Progressed on or After Platinum-Based Chemotherapy and Anti-PD-(L)1 Antibody
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.
Enrollment: 377.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-27
Primary completion date: 2023-12-20
Completion date: 2023-12-20
Plan to share individual participant data: YES
Clinical trial NCT04861948: IBI188 Combination Therapy in Solid Tumors
Official title: Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced Malignancies
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: No signs of efficacy in solid tumors
Enrollment: 9.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-05-25
Primary completion date: 2022-07-30
Completion date: 2022-07-30
Clinical trial NCT03781479: Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Official title: A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridine Phosphate in Ambulatory Patients With Spinal Muscular Atrophy (SMA) Type 3
Sponsor: Catalyst Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-21
Primary completion date: 2020-07-23
Completion date: 2020-07-23
Baseline population: The analysis of baseline characteristics included all patients in the Safety population, who are those patients who enrolled and received at least one dose of amifampridine. Patients who began the Run-in period regardless of whether they were randomized to double blind medication on Day 0 belong to the Safety population.
Plan to share individual participant data: NO
Clinical trial NCT03395639: Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
Official title: An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 168.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-15
Primary completion date: 2021-12-03
Completion date: 2021-12-03
Baseline population: Demographic and baseline characteristics were assessed in the Intent to Treat Population (ITT).
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT04094766: Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia
Official title: A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia
Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Production plan adjustment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-01
Primary completion date: 2020-08-30
Completion date: 2020-08-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03900754: A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
Official title: A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia
Sponsor: VA Office of Research and Development (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Inadequate Subject Recruitment
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-13
Primary completion date: 2024-01-31
Completion date: 2024-01-31
Plan to share individual participant data: NO